Minneapolis-based Medafor makes plant-based hemostatic agents including the Arista MPH agent, which won CE Mark approval in the European Union in 2003 and garnered FDA approval for surgical use in 2006.īard, based in Murray Hill, N.J., said the deal is aimed at expanding its Davol subsidiary’s reach into the operating suite. Bard (NYSE: BCR) said it agreed to pay $200 million up front and another possible $80 million for Medafor and its line of anti-bleeding agents.
